Quarterly report [Sections 13 or 15(d)]

Schedule of Accounts Payable to Related Party (Details)

v3.25.1
Schedule of Accounts Payable to Related Party (Details) - Cytovance Biologics Inc [Member] - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Defined Benefit Plan Disclosure [Line Items]    
Beginning balance $ 1,183,000 [1] $ 3,515,000
Invoices, net 532,000 269,000
Payments in cash (268,000) (1,800,000)
Payments in pre-funded warrants, at fair value (847,000)
Ending balance $ 600,000 [1] $ 1,984,000
[1] Accounts Payable to Cytovance Biologics, Inc. (“Cytovance”), a Related Party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock. See Note 7 – Commitments and Contingencies, Significant Agreements.